The investment objective of the C WorldWide Biotechnology fund is to achieve long-term capital growth by investing globally in a limited number of biotechnology companies. Investments are made in small and medium-sized fast-growing and research-intensive companies.
Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.
Our investment decisions are based on thorough, fundamental equity research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.
|C WorldWide Biotechnology||Benchmark|
TOP 10 HOLDINGS
|Share in %|
|Gilead Sciences||8.7 %|
|Vertex Pharmaceuticals||6.7 %|
|Biomarin Pharma||4.4 %|
|Alexion Pharmaceuticals||4.1 %|
|Dynavax Technologies||3.0 %|
|Clovis Oncology||2.6 %|
|Portola Pharmaceuticals||2.5 %|
RETURN & RISK
|1 Y||3 Y||5 Y||10 Y||Lifetime||P.A.|
|C WorldWide Biotechnology (%)||15.7||5.2||16.6||13.2||7.0||7.0|
|Relative performance (%)||6.0||-4.5||-4.7||-4.1||2.8||2.8|
|3 Y||5 Y||10 Y||Lifetime||P.A.|
|Std. dev. portfolio (%)||32.1||28.9||23.9||26.1||26.1|
|Std. dev. benchmark (%)||26.5||25.3||22.0||25.8||25.8|
|Security identifier (ISIN):||LU0119485372|
|Launch date:||8 November 2000|
|Management fee:||1.10% per annum|
|Minimum investment:||EUR 1,000|
|Benchmark:||NASDAQ Biotechnology Index®|
|NAV at month end:||31.37|
|Fund AUM:||13.8 million|
|Investment Manager:||C WorldWide Asset Management, Stockholm|
|Portfolio Manager:||Ulf Arvidsson|
The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.
All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.
It is emphasized that the figures in the fact sheet are historical, and that past performance is no reliable indicator of future performance.